AZR

Azora Therapeutics, Inc. (DE) AZR

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q3 2026
$2.81M total
Reading the latest SEC filing…

Key Metrics

Net Income

Q3 2026
EDGAR

EPS (Diluted)

Q3 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/AZR

Earnings Per Share

13fpro.ai/company/AZR

Loading ratio trend…

AZR insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Azora Therapeutics, Inc. (DE) (AZR): stock profile, AI score and financials

Azora Therapeutics, Inc. (DE) (AZR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. AZR is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of AZR by reported 13-F value include KVP Capital Advisors, DIADEMA PARTNERS, ACUTA CAPITAL PARTNERS, based on the most recent SEC filings. AZR trades on the Nasdaq exchange and files with the SEC under CIK 1513525. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AZR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Azora Therapeutics, Inc. (DE) directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1513525 →